Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — H1 2021 Earnings Presentation
18 slides from Innate Pharma Sa Class A's earnings presentation, Sep 15, 2021
Slide 1: Half Year 2021 Business Update
Half Year 2021 Business Update September 15, 2021 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved.
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Mondher Mahjoubi, MD Chief Executive Officer Chairman of the Executive Board Joyson Karakunnel, MD, MSc, FACP Frédéric Lombard, MBA EVP, Chief Medical Officer SVP, Chief Financial Officer 3
Slide 4: Innate's Approach: Harnessing Innate Immunity in Cancer
Innate’s Approach: Harnessing Innate Immunity in Cancer Choosing the right targets to leverage the body’s immune response Priming and activation (APCs and T cells) Engage NK cells 1 towards tumor Cancer antigen presentation (DCs) Lacutamab (KIR3DL2) Lymph node Trafficking of (NKp46) T cells to tumor
Slide 5: Our Robust Pipeline of Proprietary & Partnered Assets
Our Robust Pipeline of Proprietary & Partnered Assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status Sézary Syndrome PHASE 2 (FDA FAST TRACK/EMA PRIME DESIGNATION) Phase 2 data expected 2022 Early data presented Mycosis Fungoides PHASE 2 Phase 2 data expected 2022 Lacutamab KI
Slide 6: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Drive near-term Advance our Build sustainable value with innovative R&D business through Lacutamab pipeline partnerships • TELLOMAK Cohort 2 (KIR3DL2- • Sanofi advanced lead NKCE • Strong monalizumab collaboration expressing MF) advance
Slide 7: Lacutamab: Lead Proprietary Asset
LACUTAMAB Lacutamab: Lead Proprietary Asset First-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody lacutamab • Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL) KIR3DL2 • Compelling Phase 1 data in Sézary syndrome (SS), published in Lancet Oncolog
Slide 8: Development Strategy for Lacutamab Across T-Cell Lymphomas
LACUTAMAB Development Strategy for Lacutamab Across T-Cell Lymphomas Sezary ~80–200 patients* Cutaneous Syndrome T-Cell Lymphoma Fast to market approach (CTCL) Niche indication with high unmet need Mycosis Fungoides 2,200–4,000 patients* Expand potential beyond SS Explore impact of KIR3DL2 expressio
Slide 9: TELLOMAK Phase 2 Study in Two CTCL Subtypes
LACUTAMAB TELLOMAK Phase 2 Study in Two CTCL Subtypes Potential for Sézary syndrome cohort to serve as pivotal trial Sézary Syndrome (N~60) Mycosis Fungoides (N~90) ≥ 2 prior systemic therapies ≥ 2 prior systemic therapies Cohort 1 Cohort 2 Cohort 3 All comers, SS, must include KIR3DL2 expressing, K
Slide 10: Encouraging Preliminary Results in MF Cohort of TELLOMAK Trial
LACUTAMAB Encouraging Preliminary Results in MF Cohort of TELLOMAK Trial Overall response rate of ~35%* in advanced patient population with no current standard of care Cohort 2 Skin (N = 17) 4 confirmed (1CR, 3PR) & 2 not yet confirmed (uPR) global responses** 9 confirmed (1CR, 8PR) & 2 not yet conf
Slide 11: Initiating Data-Driven Strategy in PTCL
LACUTAMAB Initiating Data-Driven Strategy in PTCL N O W N E X T S T E P S RELAPSED SETTING 03 FRONTLINE Highest unmet medical need; Driven by data in the relapsed two-pronged approach: setting to advance into earlier lines 02 • Monotherapy (Phase 1b study in H2 2021) • Combination with CHOP • Combin
Slide 12: ANKET: Innate's Proprietary NK Cell Engager Platform
ANKET ANKET™: Innate’s Proprietary NK Cell Engager Platform ANKET™ Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46 is a versatile, fit-for- purpose technology that is creating Provides proliferation and activation signals a
Slide 13: Optimal Efficacy Requires All Arms in Tetra-specific ANKET
ANKETTM Optimal Efficacy Requires All Arms in Tetra-specific ANKET™ Demonstrate Superiority in Preclinical Model of Tumors TAg: Tumor antigen *ADCC-enhanced mAb 13
Slide 14: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams
MONALIZUMAB Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams Innate’s first Phase 3 program, sponsored by AstraZeneca, for patients with IO-pretreated SCCHN Promotes Anti-tumor Immunity by 2020: Phase 3 Start Triggered First of Two Unleashing Both T and NK Cells $50M
Slide 15: First Half 2021 Financial Highlights
First Half 2021 Financial Highlights Cash, cash equivalents and financial assets: €159.4m* as of June 30, 2021 • Sufficient to fund operations until at least 2022 Revenue/other income: Operating expenses: €15.7m €41.1m Licensing and collaborations: €8.3m 53% expenses related to R&D • €6.1m for monal
Slide 16: Key Newsflow Over the Next Months
Key Newsflow Over the Next 18 Months H 2 2 0 2 1 Data Readouts Clinical Progress • Monalizumab Adj NSCLC Phase 2 COAST data (AstraZeneca) • Lacutamab PTCL mono Phase 1b start • Monalizumab Cohort 3 data Phase 2 combo HNSCC • Lacutamab PTCL combo Phase 2 start (IST) • IPH5301 (CD73) Phase 1 start • A
Slide 17: Early R&D focus to drive value through later stage partnerships
Early R&D focus to drive value through later stage partnerships Drive near-term value Advance our Build sustainable with Lacutamab innovative R&D business through pipeline partnerships • Advancing proprietary NK cell- • Strong monalizumab collaboration • TELLOMAK read-out with MF in targeted platfor
Slide 18: Questions and Answers
Questions and Answers &S innate pharma